A Phase 3 interventional study of 80 mg ixekizumab Dosing Regimen and 50 mg etanercept in Psoriasis, sponsored by Eli Lilly and Company. Completed at 118 sites in 12 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-06-26.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies testing ixekizumab in Psoriasis — 5 open to participants now, 5 under way, none of them phase 3. ixekizumab · Psoriasis.
Among the 22 studies testing ixekizumab in Psoriasis, this one is the 4th largest by enrollment, is one of 3 that started in 2012, is one of 11 in phase 3, and was the 3rd registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →5 of the 22 studies testing ixekizumab in Psoriasis are open now, in 4 countries. Recruiting first, the newest first:
University Hospital, Ghent · Sites in Belgium
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–75 · Healthy volunteers
Singapore General Hospital · Sites in Singapore
Ages 22–90
University of California, San Francisco · Sites in United States
Ages 18+
Second Affiliated Hospital, School of Medicine, Zhejiang University
Ages 70+
By country, each count listing its studies:
ixekizumab: first FDA approval 2016 (TALTZ), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 3 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,224 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 156 across the 22 interventional studies. Of the 17 that completed or were terminated, 16 (94%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 22 have an industry lead sponsor. The 6 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
36 studies in Psoriasis by Eli Lilly and Company: 1 open now, 1 under way, none of them phase 3. Of 35 finished, 28 (80%) have results posted.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one is the 6th largest by enrollment, is one of 3 that started in 2012, is one of 15 in phase 3, and was the 5th registered.
Eli Lilly and Company’s Psoriasis studies by the year they started, since 2009.
None of the studies under way reaches primary completion within a year.
Among the 22 studies testing ixekizumab in Psoriasis, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Eli Lilly and Company’s 36 in Psoriasis:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study will assess the safety and efficacy of ixekizumab (LY2439821) compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered by two 80 mg subcutaneous (SC) injections at Week 0, then one 80 mg SC injection per Dosing Regimen 1 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.
Drug: 80 mg ixekizumab Dosing Regimen
Administered by two 80 mg SC injections at Week 0, then one 80 mg SC injection per Dosing Regimen 2 until Week 12. At Week 12, ixekizumab responders are re-randomized to placebo, Dosing Regimen 2 or Dosing Regimen 3. Ixekizumab non-responders are assigned to Dosing Regimen 2.
Drug: 80 mg ixekizumab Dosing Regimen
Dosing Regimen 3 is not used until Week 12. At Week 12, ixekizumab responders re-randomized to this arm will receive Dosing Regimen 3.
Drug: 80 mg ixekizumab Dosing Regimen
Administered by one 50 mg SC injection twice weekly starting at Week 0 up to Week 12. At Week 12, etanercept responders are assigned to placebo, and nonresponders to Dosing Regimen 2.
Drug: 50 mg etanercept
Placebo for ixekizumab administered by two SC injections at Week 0, then one SC injection per Dosing Regimen 1 until Week 12. At Week 12, placebo responders are assigned to placebo, and nonresponders to Dosing Regimen 2. Placebo for etanercept administered by one SC injection twice weekly starting at Week 0 up to Week 12 was used to blind etanercept injections for Dosing Regimen 1, Dosing Regimen 2, and Placebo Comparator groups.
Drug: Placebo
Administered SC
Also known as: LY2439821
Administered SC
Administered SC
Percentage of Participants With a Static Physician Global Assessment (sPGA) of (0,1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA])
The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.
Time frame: Week 12
Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) ≥75% (PASI75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI])
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.
Time frame: Week 12
Percentage of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [sPGA])
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).
Time frame: Week 12
Percentage of Participants Achieving PASI 90% (PASI90) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [PASI])
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI90 were defined as having an improvement of ≥90% in the PASI score compared to baseline.
Time frame: Week 12
Percentage of Participants Achieving PASI 100% (PASI100)
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI100 were defined as having an improvement of 100% in the PASI score compared to baseline.
Time frame: Week 12
Percentage of Participants Maintaining an sPGA (0,1) From Week 12 After Re-randomization at Start of Maintenance Dosing Period to Week 60
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).
Time frame: Week 60
Percentage of Participants With Itching Severity (Itch Numeric Rating Scale [NRI]) Score ≥4 Point Reduction From Baseline
The Itch Numeric Rating Scale (NRS) is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable". The number and percentage of participants achieving an Itch NRS ≥4 point reduction from baseline were presented by treatment group for participants who had a baseline Itch NRS ≥4. Describes worst level of itching in past 24 hours.
Time frame: Week 12
Change From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Total Score (Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes [PRO])
DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much); and "not relevant" and unanswered responses were scored as "0." Total scores range from 0 to 30, with higher score indicating greater quality of life impairment. A 5-point change from baseline is considered clinically relevant. Least Squares (LS) Mean change from baseline was calculated using mixed model repeated measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
Time frame: Baseline, Week 12
Change From Baseline in Nail Psoriasis Severity Index (NAPSI)
The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps. The fingernail bed and fingernail matrix are each divided into quadrants. Each fingernail is given a score for fingernail bed Ps and fingernail matrix Ps, each with scores of 0 (none) to 4 (Ps in all 4 quadrants), depending on the presence (score of 1) or absence (score of 0) of Ps in each quadrant of the fingernail bed or matrix. The NAPSI score of a fingernail is the sum of scores from each quadrant of the fingernail bed and fingernail matrix (maximum of 8). The total NAPSI score equals the sum of all fingernails and ranges from 0 to 80 with higher scores indicating more severe Ps. LS mean change from baseline in NAPSI score was calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
Time frame: Baseline, Week 12
Change From Baseline Psoriasis Scalp Severity Index (PSSI) Score
The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total scores range from 0 (less severity) to 72 (more severity), with lower scores indicating less severity. LS mean change from baseline in PSSI score was calculated using MMRM with baseline score as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.
Time frame: Baseline, Week 12
Change From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis
The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS mean change from baseline in BSA was calculated using MMRM with baseline BSA as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.
Time frame: Baseline, Week 12
Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score
The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance \[initial, middle and late insomnia or hypersomnia\], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. LS mean change from baseline in total QIDS-SR16 score was calculated using the analysis of covariance (ANCOVA) model with treatment, pooled center and baseline QIDS total score.
Time frame: Baseline, Week 12
Change From Baseline in All Scores of the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO)
The (WPAI-PSO) is a 6-item instrument used to assess the impact of psoriasis on productivity impairment within the past 7 days and has four domains, namely, absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism, overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as each score \* 100 and ranges from 0 to 100; greater scores indicate greater impairment. LS mean change from baseline in each WPAI-PSO score was calculated using the (ANCOVA) model with treatment, pooled center and baseline WPAI value.
Time frame: Baseline, Week 12
Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) and Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean change from baseline in SF-36 score was calculated using the ANCOVA model with treatment, pooled center and baseline SF-36 score.
Time frame: Baseline, Week 12
Change From Baseline in Patient's Global Assessment (PatGA) of Disease Severity
The Patient's Global Assessment of Disease Severity is a single-item patient reported outcome measure on which participants are asked to rate by circling a number on a 0 to 5 NRS the severity of their psoriasis "today" from 0 (Clear) = no psoriasis to 5 (Severe) = the worst their psoriasis has ever been. LS mean change from baseline in patient's global assessment of disease severity score was calculated using (MMRM) with baseline score as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.
Time frame: Baseline, 12 weeks
Percentage of Participants Achieving Palmoplantar PASI (PPASI) of ≥50% (PPASI50), ≥75% (PPASI75) or 100% (PPASI100) Improvement
The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. Participants achieving PPASI50, PPASI75 or PASI100 were defined as having an improvement of at least 50%, 75%, or of 100%, respectively, in the PPASI scores compared to baseline.
Time frame: Week 12
Percentage of Participants With Anti-Ixekizumab Antibodies
Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the # of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
Time frame: Baseline to Week 12
| Milestone | Placebo- Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Ixe/Placebo- Maintenance Period Primary Population (Pop) | Ixe/Ixe Q4W - Maintenance Period Primary Pop | Ixe/Ixe Q12W - Maintenance Period Primary Pop | Placebo Resp/Placebo - Maintenance Period Secondary Pop | Placebo NonResp/Ixe Q4W - Maintenance Period Secondary Pop | ETN Resp/Placebo Maintenance Period Secondary Pop | ETN NonResp/Ixe Q4W - Maintenance Period Secondary Pop | Ixe Q4W NonResp/Ixe Q4W - Maintenance Period Secondary Pop | Ixe Q2W NonResp/Ixe Q4W - Maintenance Period Secondary Pop | Placebo Long-Term Extension (LTE) | Ixe Long-Term Extension | Total Ixe Long-Term Extension | Placebo Post-Treatment Follow-Up | ETN Post-Treatment Follow-Up | Ixe Q12W Post-Treatment Follow-Up | Ixe Q4W Post-Treatment Follow-Up | Ixe Q2W Post-Treatment Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 168 | 358 | 347 | 351 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Received at least 1 dose of study drug | 167 | 357 | 347 | 350 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 158 | 333 | 328 | 342 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 10 | 25 | 19 | 9 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 5 | 5 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 8 | 6 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 2 | 4 | 5 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 1 | 5 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 3 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo- Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Ixe/Placebo- Maintenance Period Primary Population (Pop) | Ixe/Ixe Q4W - Maintenance Period Primary Pop | Ixe/Ixe Q12W - Maintenance Period Primary Pop | Placebo Resp/Placebo - Maintenance Period Secondary Pop | Placebo NonResp/Ixe Q4W - Maintenance Period Secondary Pop | ETN Resp/Placebo Maintenance Period Secondary Pop | ETN NonResp/Ixe Q4W - Maintenance Period Secondary Pop | Ixe Q4W NonResp/Ixe Q4W - Maintenance Period Secondary Pop | Ixe Q2W NonResp/Ixe Q4W - Maintenance Period Secondary Pop | Placebo Long-Term Extension (LTE) | Ixe Long-Term Extension | Total Ixe Long-Term Extension | Placebo Post-Treatment Follow-Up | ETN Post-Treatment Follow-Up | Ixe Q12W Post-Treatment Follow-Up | Ixe Q4W Post-Treatment Follow-Up | Ixe Q2W Post-Treatment Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 176 | 187 | 181 | 3 | 155 | 132 | 200 | 75 | 49 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants received one dose | 0 | 0 | 0 | 0 | 176 | 187 | 181 | 3 | 155 | 132 | 200 | 75 | 49 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 15 | 149 | 92 | 0 | 135 | 11 | 178 | 56 | 37 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 161 | 38 | 89 | 3 | 20 | 121 | 22 | 19 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: On study treatment | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Relapsed | 0 | 0 | 0 | 0 | 150 | 22 | 80 | 2 | 0 | 114 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 3 | 0 | 2 | 10 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 4 | 6 | 6 | 1 | 8 | 2 | 8 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 3 | 3 | 1 | 0 | 4 | 1 | 6 | 5 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 3 | 1 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 3 | 4 | 1 | 0 | 1 | 2 | 2 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo- Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Ixe/Placebo- Maintenance Period Primary Population (Pop) | Ixe/Ixe Q4W - Maintenance Period Primary Pop | Ixe/Ixe Q12W - Maintenance Period Primary Pop | Placebo Resp/Placebo - Maintenance Period Secondary Pop | Placebo NonResp/Ixe Q4W - Maintenance Period Secondary Pop | ETN Resp/Placebo Maintenance Period Secondary Pop | ETN NonResp/Ixe Q4W - Maintenance Period Secondary Pop | Ixe Q4W NonResp/Ixe Q4W - Maintenance Period Secondary Pop | Ixe Q2W NonResp/Ixe Q4W - Maintenance Period Secondary Pop | Placebo Long-Term Extension (LTE) | Ixe Long-Term Extension | Total Ixe Long-Term Extension | Placebo Post-Treatment Follow-Up | ETN Post-Treatment Follow-Up | Ixe Q12W Post-Treatment Follow-Up | Ixe Q4W Post-Treatment Follow-Up | Ixe Q2W Post-Treatment Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26 | 979 | 1002 | 0 | 0 | 0 | 0 | 0 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 754 | 774 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26 | 225 | 228 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 69 | 70 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 62 | 63 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 38 | 38 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 26 | 26 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 11 | 12 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 8 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 6 | 6 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Clinical relapse | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | 4 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Switched from pbo to ixe | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 23 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Placebo- Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Ixe/Placebo- Maintenance Period Primary Population (Pop) | Ixe/Ixe Q4W - Maintenance Period Primary Pop | Ixe/Ixe Q12W - Maintenance Period Primary Pop | Placebo Resp/Placebo - Maintenance Period Secondary Pop | Placebo NonResp/Ixe Q4W - Maintenance Period Secondary Pop | ETN Resp/Placebo Maintenance Period Secondary Pop | ETN NonResp/Ixe Q4W - Maintenance Period Secondary Pop | Ixe Q4W NonResp/Ixe Q4W - Maintenance Period Secondary Pop | Ixe Q2W NonResp/Ixe Q4W - Maintenance Period Secondary Pop | Placebo Long-Term Extension (LTE) | Ixe Long-Term Extension | Total Ixe Long-Term Extension | Placebo Post-Treatment Follow-Up | ETN Post-Treatment Follow-Up | Ixe Q12W Post-Treatment Follow-Up | Ixe Q4W Post-Treatment Follow-Up | Ixe Q2W Post-Treatment Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16 | 6 | 24 | 656 | 248 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 14 | 489 | 212 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 16 | 6 | 10 | 167 | 36 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9 | 5 | 8 | 63 | 13 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 41 | 13 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 29 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 14 | 4 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 9 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 6 | 2 |
| Withdrew: Entry criteria not met | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 3 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 |
| Withdrew: Clinical relapse | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
The sPGA is the physician's determination of the participant's Psoriasis (Ps) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.
| percentage of participants | Placebo - Induction Period | 50 mg Etanercept (ETN) - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|---|---|---|---|
| Percentage of Participants With a Static Physician Global Assessment (sPGA) of (0,1) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Static Physician Global Assessment [sPGA]) | 2.4 | 36.0 | 72.9 | 83.2 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI75 were defined as having an improvement of ≥75% in the PASI score compared to baseline.
| percentage of participants | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|---|---|---|---|
| Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) ≥75% (PASI75) Improvement (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: Psoriasis Area and Severity Index [PASI]) | 2.4 | 41.6 | 77.5 | 89.7 |
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).
| percentage of participants | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|---|---|---|---|
| Percentage of Participants Achieving an sPGA (0) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [sPGA]) | 0.6 | 5.9 | 32.3 | 41.9 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI90 were defined as having an improvement of ≥90% in the PASI score compared to baseline.
| percentage of participants | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|---|---|---|---|
| Percentage of Participants Achieving PASI 90% (PASI90) (Efficacy of Ixekizumab in Participants With Moderate to Severe Chronic Plaque Psoriasis. Measure: [PASI]) | 0.6 | 18.7 | 59.7 | 70.7 |
The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor (head \[0.1\], upper limbs \[0.2\], trunk \[0.3\], lower limbs \[0.4\]). Overall scores range from 0 (no Ps) to 72 (the most severe disease). Participants achieving PASI100 were defined as having an improvement of 100% in the PASI score compared to baseline.
| percentage of participants | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|---|---|---|---|
| Percentage of Participants Achieving PASI 100% (PASI100) | 0.6 | 5.3 | 30.8 | 40.5 |
The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's Ps was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe).
| Percentage of participants | Ixe/Placebo- Maintenance Period Primary Pop | Ixe/Ixe Q12W - Maintenance Period Primary Pop | Ixe/Ixe Q4W - Maintenance Period Primary Pop |
|---|---|---|---|
| Percentage of Participants Maintaining an sPGA (0,1) From Week 12 After Re-randomization at Start of Maintenance Dosing Period to Week 60 | 6.3 | 40.9 | 74.9 |
The Itch Numeric Rating Scale (NRS) is a participant-administered, 11-point horizontal scale anchored at 0 and 10, with 0 representing "no itch" and 10 representing "worst itch imaginable". The number and percentage of participants achieving an Itch NRS ≥4 point reduction from baseline were presented by treatment group for participants who had a baseline Itch NRS ≥4. Describes worst level of itching in past 24 hours.
| percentage of participants | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|---|---|---|---|
| Percentage of Participants With Itching Severity (Itch Numeric Rating Scale [NRI]) Score ≥4 Point Reduction From Baseline | 14.1 | 57.8 | 76.8 | 85.1 |
DLQI is a participant-administered, 10-question, validated, quality-of-life questionnaire that covers 6 domains, including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include 0 (not at all), 1 (a little), 2 (a lot), and 3 (very much); and "not relevant" and unanswered responses were scored as "0." Total scores range from 0 to 30, with higher score indicating greater quality of life impairment. A 5-point change from baseline is considered clinically relevant. Least Squares (LS) Mean change from baseline was calculated using mixed model repeated measures (MMRM) with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
| units on a scale | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|---|---|---|---|
| Change From Baseline in Dermatology-Specific Quality of Life Index (DLQI) Total Score (Quality of Life and Outcome Assessments. Measures: Participant Reported Outcomes [PRO]) | -2.0 ± 0.36 | -7.7 ± 0.25 | -9.4 ± 0.25 | -10.4 ± 0.25 |
The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix Ps. The fingernail bed and fingernail matrix are each divided into quadrants. Each fingernail is given a score for fingernail bed Ps and fingernail matrix Ps, each with scores of 0 (none) to 4 (Ps in all 4 quadrants), depending on the presence (score of 1) or absence (score of 0) of Ps in each quadrant of the fingernail bed or matrix. The NAPSI score of a fingernail is the sum of scores from each quadrant of the fingernail bed and fingernail matrix (maximum of 8). The total NAPSI score equals the sum of all fingernails and ranges from 0 to 80 with higher scores indicating more severe Ps. LS mean change from baseline in NAPSI score was calculated using MMRM with baseline score as covariate, treatment, pooled center, visit and treatment-by-visit interaction as fixed effects.
| units on a scale | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|---|---|---|---|
| Change From Baseline in Nail Psoriasis Severity Index (NAPSI) | -0.82 ± 1.162 | -5.34 ± 0.835 | -7.39 ± 0.843 | -8.60 ± 0.853 |
The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total scores range from 0 (less severity) to 72 (more severity), with lower scores indicating less severity. LS mean change from baseline in PSSI score was calculated using MMRM with baseline score as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.
| units on a scale | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|---|---|---|---|
| Change From Baseline Psoriasis Scalp Severity Index (PSSI) Score | -3.8 ± 0.73 | -14.8 ± 0.50 | -18.5 ± 0.51 | -18.7 ± 0.50 |
The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a continuous scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS mean change from baseline in BSA was calculated using MMRM with baseline BSA as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.
| units on a scale | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|---|---|---|---|
| Change From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis | 0.5 ± 1.05 | -12.4 ± 0.72 | -20.3 ± 0.72 | -20.6 ± 0.71 |
The QIDS-SR16 is a self-administered, 16-item instrument in which a participant is asked to consider each statement as it relates to the way they have felt for the past 7 days. There is a 4-point scale for each item ranging from 0 (best) to 3 (worst). The 16 items are scored to give 9 individual depression domains (sad mood, concentration, self-criticism, suicidal ideation, interest, energy/fatigue, sleep disturbance \[initial, middle and late insomnia or hypersomnia\], decrease/increase in appetite/weight, and psychomotor agitation/retardation), which are summed to give a single score ranging from 0 to 27, with higher scores denoting greater symptom severity. LS mean change from baseline in total QIDS-SR16 score was calculated using the analysis of covariance (ANCOVA) model with treatment, pooled center and baseline QIDS total score.
| units on a scale | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|---|---|---|---|
| Change From Baseline in Quick Inventory of Depressive Symptomatology-Self Report 16 Items (QIDS-SR16) Total Score | 0.1 ± 0.21 | -0.3 ± 0.15 | -0.7 ± 0.15 | -0.9 ± 0.15 |
The (WPAI-PSO) is a 6-item instrument used to assess the impact of psoriasis on productivity impairment within the past 7 days and has four domains, namely, absenteeism, presenteeism (reduced productivity while at work), an overall work impairment score, and impairment in daily activities performed outside of work. Four scores are derived as percentages: absenteeism, presenteeism, overall work impairment (absenteeism and presenteeism), and impairment in activities performed outside of work. Percentage is calculated as each score \* 100 and ranges from 0 to 100; greater scores indicate greater impairment. LS mean change from baseline in each WPAI-PSO score was calculated using the (ANCOVA) model with treatment, pooled center and baseline WPAI value.
| units on a scale | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|---|---|---|---|
| Absenteeism | -1.5 ± 0.83 | -3.7 ± 0.55 | -3.2 ± 0.54 | -3.9 ± 0.54 |
| Activity Impairment Score | -0.4 ± 1.46 | -16.6 ± 1.00 | -22.6 ± 1.02 | -25.8 ± 1.01 |
| Presenteeism Score | -2.4 ± 1.59 | -12.4 ± 1.05 | -18.5 ± 1.03 | -18.2 ± 1.03 |
| Work Productivity Loss Score | -2.0 ± 1.80 | -13.7 ± 1.18 | -19.3 ± 1.18 | -19.5 ± 1.18 |
The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. The 8 domains are regrouped into the PCS and MCS scores. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. In this study, the SF-36 acute version was used, which has a 1 week recall period. LS mean change from baseline in SF-36 score was calculated using the ANCOVA model with treatment, pooled center and baseline SF-36 score.
| units on a scale | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|---|---|---|---|
| Physical Summary Score | -0.4495 ± 0.5226 | 2.5498 ± 0.3610 | 4.5726 ± 0.3628 | 3.7964 ± 0.3575 |
| Mental Summary Score | -0.0955 ± 0.5886 | 2.3221 ± 0.4065 | 2.8504 ± 0.4090 | 4.5142 ± 0.4026 |
The Patient's Global Assessment of Disease Severity is a single-item patient reported outcome measure on which participants are asked to rate by circling a number on a 0 to 5 NRS the severity of their psoriasis "today" from 0 (Clear) = no psoriasis to 5 (Severe) = the worst their psoriasis has ever been. LS mean change from baseline in patient's global assessment of disease severity score was calculated using (MMRM) with baseline score as a covariate, treatment, pooled center, visit, and treatment-by-visit interaction as fixed effects.
| units on a scale | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|---|---|---|---|
| Change From Baseline in Patient's Global Assessment (PatGA) of Disease Severity | -0.4 ± 0.09 | -2.1 ± 0.06 | -3.0 ± 0.06 | -3.2 ± 0.06 |
The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 to 72. The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. Participants achieving PPASI50, PPASI75 or PASI100 were defined as having an improvement of at least 50%, 75%, or of 100%, respectively, in the PPASI scores compared to baseline.
| percentage of participants | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|---|---|---|---|
| PPASI 50 | 43.6 | 71.6 | 85.3 | 88.5 |
| PPASI 75 | 30.9 | 61.1 | 80.4 | 79.8 |
| PPASI 100 | 25.5 | 50.5 | 69.6 | 71.2 |
Percentage of participants with treatment-emergent positive anti-ixekizumab antibodies was summarized by treatment group. Percentage was calculated based on the # of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.
| percentage of participants | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period |
|---|---|---|---|---|
| Percentage of Participants With Anti-Ixekizumab Antibodies | 0 | 2.9 | 14.1 | 10.4 |
Collected over Up to 288 Weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo - Induction Period | — | 3/167 (1.8%) | 48/167 (28.7%) |
| 50 mg ETN - Induction Period | — | 8/357 (2.2%) | 141/357 (39.5%) |
| Ixe Q4W - Induction Period | — | 8/347 (2.3%) | 116/347 (33.4%) |
| Ixe Q2W - Induction Period | — | 5/350 (1.4%) | 140/350 (40%) |
| Ixe/Placebo- Maintenance Period Primary Pop | — | 8/176 (4.5%) | 56/176 (31.8%) |
| Ixe/Ixe Q4W - Maintenance Period Primary Pop | — | 12/187 (6.4%) | 100/187 (53.5%) |
| Ixe/Ixe Q12W - Maintenance Period Primary Pop | — | 14/181 (7.7%) | 87/181 (48.1%) |
| Placebo Resp/Placebo - Maintenance Period Secondary Pop | — | 0/3 (0%) | 2/3 (66.7%) |
| Placebo NonResp/Ixe Q4W - Maintenance Period Secondary Pop | — | 13/155 (8.4%) | 77/155 (49.7%) |
| ETN Resp/Placebo Maintenance Period Secondary Pop | — | 2/132 (1.5%) | 42/132 (31.8%) |
| ETN NonResp/Ixe Q4W - Maintenance Period Secondary Pop | — | 9/200 (4.5%) | 106/200 (53%) |
| Ixe Q4W NonResp/Ixe Q4W- Maintenance Period Secondary Pop | — | 4/75 (5.3%) | 27/75 (36%) |
| Ixe Q2W NonResp/Ixe Q4W Maintenance Period Secondary Pop | — | 2/49 (4.1%) | 26/49 (53.1%) |
| Ixe Q4W Maintenance Period Relapsed Pop | — | 14/368 (3.8%) | 136/368 (37%) |
| Placebo Long-Term Extension | — | 1/26 (3.8%) | 7/26 (26.9%) |
| Ixe Long-Term Extension | — | 107/979 (10.9%) | 345/979 (35.2%) |
| Total Ixe Long-Term Extension | — | 107/1,002 (10.7%) | 345/1,002 (34.4%) |
| Placebo Post-Treatment Follow-Up | — | 1/16 (6.3%) | 2/16 (12.5%) |
| ETN Post-Treatment Follow-Up | — | 0/6 (0%) | 3/6 (50%) |
| Ixe Q2W Post-Treatment Follow-Up | — | 3/248 (1.2%) | 21/248 (8.5%) |
| Ixe Q4W Post-Treatment Follow-Up | — | 12/656 (1.8%) | 34/656 (5.2%) |
| Ixe Q12W Post-Treatment Follow-Up | — | 0/24 (0%) | 0/24 (0%) |
| Event | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Ixe/Placebo- Maintenance Period Primary Pop | Ixe/Ixe Q4W - Maintenance Period Primary Pop | Ixe/Ixe Q12W - Maintenance Period Primary Pop | Placebo Resp/Placebo - Maintenance Period Secondary Pop | Placebo NonResp/Ixe Q4W - Maintenance Period Secondary Pop | ETN Resp/Placebo Maintenance Period Secondary Pop | ETN NonResp/Ixe Q4W - Maintenance Period Secondary Pop | Ixe Q4W NonResp/Ixe Q4W- Maintenance Period Secondary Pop | Ixe Q2W NonResp/Ixe Q4W Maintenance Period Secondary Pop | Ixe Q4W Maintenance Period Relapsed Pop | Placebo Long-Term Extension | Ixe Long-Term Extension | Total Ixe Long-Term Extension | Placebo Post-Treatment Follow-Up | ETN Post-Treatment Follow-Up | Ixe Q2W Post-Treatment Follow-Up | Ixe Q4W Post-Treatment Follow-Up | Ixe Q12W Post-Treatment Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Myocardial infarctionCardiac disorders | 0/167 | 1/357 | 0/347 | 0/350 | 0/176 | 0/187 | 0/181 | 0/3 | 1/155 | 0/132 | 0/200 | 0/75 | 0/49 | 0/368 | 0/26 | 3/979 | 3/1002 | 1/16 | 0/6 | 1/248 | 0/656 | 0/24 |
| PhotophobiaEye disorders | 0/167 | 0/357 | 0/347 | 0/350 | 0/176 | 0/187 | 0/181 | 0/3 | 0/155 | 0/132 | 0/200 | 0/75 | 0/49 | 0/368 | 1/26 | 0/979 | 0/1002 | 0/16 | 0/6 | 0/248 | 0/656 | 0/24 |
| HeadacheNervous system disorders | 0/167 | 0/357 | 0/347 | 0/350 | 0/176 | 0/187 | 0/181 | 0/3 | 0/155 | 0/132 | 0/200 | 0/75 | 0/49 | 0/368 | 1/26 | 0/979 | 0/1002 | 0/16 | 0/6 | 0/248 | 0/656 | 0/24 |
| Sinus disorderRespiratory, thoracic and mediastinal disorders | 0/167 | 0/357 | 0/347 | 0/350 | 0/176 | 0/187 | 0/181 | 0/3 | 0/155 | 0/132 | 0/200 | 0/75 | 0/49 | 0/368 | 1/26 | 0/979 | 0/1002 | 0/16 | 0/6 | 0/248 | 0/656 | 0/24 |
| Imminent abortionPregnancy, puerperium and perinatal conditions | 0/48 | 0/122 | 0/103 | 0/129 | 0/66 | 0/56 | 0/61 | 0/2 | 1/43 | 0/43 | 0/74 | 0/22 | 0/19 | 0/129 | 0/12 | 0/313 | 0/324 | 0/6 | 0/1 | 0/78 | 0/203 | 0/10 |
| Peritonsillar abscessInfections and infestations | 0/167 | 0/357 | 0/347 | 0/350 | 0/176 | 0/187 | 0/181 | 0/3 | 0/155 | 0/132 | 0/200 | 0/75 | 1/49 | 0/368 | 0/26 | 0/979 | 0/1002 | 0/16 | 0/6 | 0/248 | 0/656 | 0/24 |
| NephrolithiasisRenal and urinary disorders | 0/167 | 1/357 | 0/347 | 0/350 | 0/176 | 0/187 | 0/181 | 0/3 | 0/155 | 0/132 | 0/200 | 0/75 | 1/49 | 1/368 | 0/26 | 0/979 | 0/1002 | 0/16 | 0/6 | 0/248 | 0/656 | 0/24 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/48 | 0/122 | 0/103 | 0/129 | 1/66 | 0/56 | 0/61 | 0/2 | 0/43 | 0/43 | 0/74 | 0/22 | 0/19 | 0/129 | 0/12 | 0/313 | 0/324 | 0/6 | 0/1 | 0/78 | 0/203 | 0/10 |
| Noninfective sialoadenitisGastrointestinal disorders | 0/167 | 0/357 | 0/347 | 0/350 | 0/176 | 0/187 | 0/181 | 0/3 | 0/155 | 0/132 | 0/200 | 1/75 | 0/49 | 0/368 | 0/26 | 0/979 | 0/1002 | 0/16 | 0/6 | 0/248 | 0/656 | 0/24 |
| PneumoniaInfections and infestations | 0/167 | 0/357 | 0/347 | 0/350 | 0/176 | 0/187 | 0/181 | 0/3 | 0/155 | 0/132 | 1/200 | 1/75 | 0/49 | 0/368 | 0/26 | 5/979 | 5/1002 | 0/16 | 0/6 | 0/248 | 1/656 | 0/24 |
| Event | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Ixe/Placebo- Maintenance Period Primary Pop | Ixe/Ixe Q4W - Maintenance Period Primary Pop | Ixe/Ixe Q12W - Maintenance Period Primary Pop | Placebo Resp/Placebo - Maintenance Period Secondary Pop | Placebo NonResp/Ixe Q4W - Maintenance Period Secondary Pop | ETN Resp/Placebo Maintenance Period Secondary Pop | ETN NonResp/Ixe Q4W - Maintenance Period Secondary Pop | Ixe Q4W NonResp/Ixe Q4W- Maintenance Period Secondary Pop | Ixe Q2W NonResp/Ixe Q4W Maintenance Period Secondary Pop | Ixe Q4W Maintenance Period Relapsed Pop | Placebo Long-Term Extension | Ixe Long-Term Extension | Total Ixe Long-Term Extension | Placebo Post-Treatment Follow-Up | ETN Post-Treatment Follow-Up | Ixe Q2W Post-Treatment Follow-Up | Ixe Q4W Post-Treatment Follow-Up | Ixe Q12W Post-Treatment Follow-Up |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Urinary tract infectionInfections and infestations | 2/167 | 2/357 | 7/347 | 5/350 | 3/176 | 5/187 | 7/181 | 1/3 | 8/155 | 0/132 | 8/200 | 1/75 | 3/49 | 4/368 | 1/26 | 27/979 | 27/1002 | 0/16 | 0/6 | 0/248 | 1/656 | 0/24 |
| Mycobacterium tuberculosis complex test positiveInvestigations | 0/167 | 0/357 | 0/347 | 0/350 | 0/176 | 3/187 | 2/181 | 1/3 | 1/155 | 0/132 | 1/200 | 0/75 | 0/49 | 2/368 | 0/26 | 5/979 | 5/1002 | 0/16 | 0/6 | 0/248 | 2/656 | 0/24 |
| Musculoskeletal chest painMusculoskeletal and connective tissue disorders | 0/167 | 1/357 | 0/347 | 2/350 | 1/176 | 0/187 | 0/181 | 1/3 | 0/155 | 0/132 | 2/200 | 0/75 | 1/49 | 0/368 | 0/26 | 3/979 | 3/1002 | 0/16 | 0/6 | 0/248 | 0/656 | 0/24 |
| NasopharyngitisInfections and infestations | 17/167 | 37/357 | 28/347 | 34/350 | 19/176 | 32/187 | 24/181 | 0/3 | 29/155 | 19/132 | 35/200 | 12/75 | 8/49 | 41/368 | 0/26 | 125/979 | 125/1002 | 0/16 | 1/6 | 3/248 | 4/656 | 0/24 |
| NauseaGastrointestinal disorders | 3/167 | 1/357 | 5/347 | 7/350 | 2/176 | 2/187 | 4/181 | 0/3 | 6/155 | 2/132 | 4/200 | 1/75 | 2/49 | 4/368 | 0/26 | 11/979 | 11/1002 | 0/16 | 1/6 | 1/248 | 2/656 | 0/24 |
| AstheniaGeneral disorders | 0/167 | 2/357 | 3/347 | 0/350 | 0/176 | 1/187 | 2/181 | 0/3 | 1/155 | 1/132 | 0/200 | 0/75 | 0/49 | 0/368 | 0/26 | 3/979 | 3/1002 | 0/16 | 1/6 | 0/248 | 0/656 | 0/24 |
| Injection site painGeneral disorders | 2/167 | 4/357 | 5/347 | 13/350 | 4/176 | 1/187 | 1/181 | 0/3 | 1/155 | 1/132 | 2/200 | 0/75 | 1/49 | 1/368 | 1/26 | 1/979 | 1/1002 | 0/16 | 1/6 | 0/248 | 0/656 | 0/24 |
| ArthritisMusculoskeletal and connective tissue disorders | 0/167 | 0/357 | 0/347 | 0/350 | 0/176 | 0/187 | 0/181 | 0/3 | 0/155 | 1/132 | 2/200 | 0/75 | 0/49 | 1/368 | 0/26 | 4/979 | 4/1002 | 0/16 | 1/6 | 1/248 | 0/656 | 0/24 |
| HeadacheNervous system disorders | 2/167 | 21/357 | 17/347 | 17/350 | 7/176 | 12/187 | 8/181 | 0/3 | 8/155 | 5/132 | 4/200 | 4/75 | 4/49 | 12/368 | 0/26 | 30/979 | 30/1002 | 0/16 | 1/6 | 1/248 | 1/656 | 0/24 |
| Upper respiratory tract infectionInfections and infestations | 7/167 | 27/357 | 16/347 | 20/350 | 14/176 | 25/187 | 21/181 | 0/3 | 20/155 | 8/132 | 21/200 | 7/75 | 7/49 | 21/368 | 2/26 | 108/979 | 108/1002 | 0/16 | 0/6 | 2/248 | 4/656 | 0/24 |
All randomized participants.
| Age, Categorical(Participants) | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 159 | 337 | 324 | 327 | 1147 |
| >=65 years | 9 | 21 | 23 | 24 | 77 |
| Sex: Female, Male(Participants) | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Total |
|---|---|---|---|---|---|
| Female | 48 | 122 | 103 | 130 | 403 |
| Male | 120 | 236 | 244 | 221 | 821 |
| Ethnicity (NIH/OMB)(Participants) | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 11 | 26 | 24 | 19 | 80 |
| Not Hispanic or Latino | 130 | 279 | 271 | 274 | 954 |
| Unknown or Not Reported | 27 | 53 | 52 | 58 | 190 |
| Race (NIH/OMB)(Participants) | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 2 | 0 | 2 | 2 | 6 |
| Asian | 6 | 8 | 11 | 12 | 37 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 1 | 0 | 3 |
| Black or African American | 10 | 13 | 11 | 5 | 39 |
| White | 149 | 331 | 315 | 330 | 1125 |
| More than one race | 0 | 1 | 3 | 1 | 5 |
| Unknown or Not Reported | 0 | 4 | 4 | 1 | 9 |
| Region of Enrollment(Participants) | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Total |
|---|---|---|---|---|---|
| Canada | 40 | 82 | 82 | 84 | 288 |
| Austria | 2 | 10 | 6 | 5 | 23 |
| Netherlands | 1 | 2 | 2 | 1 | 6 |
| Czechia | 3 | 6 | 3 | 6 | 18 |
| Romania | 6 | 9 | 8 | 12 | 35 |
| United States | 49 | 111 | 105 | 104 | 369 |
| Poland | 14 | 30 | 28 | 30 | 102 |
| United Kingdom | 4 | 9 | 9 | 11 | 33 |
| Australia | 7 | 13 | 15 | 16 | 51 |
| France | 7 | 18 | 21 | 19 | 65 |
| Germany | 28 | 53 | 51 | 47 | 179 |
| Spain | 7 | 15 | 17 | 16 | 55 |
| Baseline in Static Physician Global Assessment (sPGA)(Participants) | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Total |
|---|---|---|---|---|---|
| sPGA = 3 | 86 | 186 | 166 | 178 | 616 |
| sPGA = 4,5 | 82 | 172 | 181 | 173 | 608 |
| Baseline in Participants Achieving Psoriasis Area and Severity Index (PASI) Score(units on a scale) | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Total |
|---|---|---|---|---|---|
| Mean | 20.57 ± 8.366 | 19.07 ± 6.701 | 20.04 ± 6.962 | 19.35 ± 7.339 | 19.63 ± 7.216 |
| Baseline Dermatology-Specific Quality of Life Index (DLQI) Total Score(units on a scale) | Placebo - Induction Period | 50 mg ETN - Induction Period | Ixe Q4W - Induction Period | Ixe Q2W - Induction Period | Total |
|---|---|---|---|---|---|
| Mean | 12.8 ± 7.24 | 12.7 ± 7.03 | 11.6 ± 6.65 | 12.4 ± 6.86 | 12.3 ± 6.91 |
7 further baseline measures are reported on the registry.
Showing the first 100 of 118 sites across 12 countries. Choose a country and city above to see the rest.
Plan to share: Yes — Plan Description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from May 2012 to primary completion in Mar 2014, 22 months.
Results were first posted in Oct 2016, 2 years 6 months after primary completion. A results delay was requested in Jan 2015.
Of 217 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 26. This study's 22 months is above that.
Counting every sponsor, half of 227 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ixekizumab